Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT04300140 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

72

Enrollment

INDUSTRY

Sponsor class

Stopped Due to business reasons

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Batiraxcept
DRUG: Cabozantinib (Cabo)
DRUG: Nivolumab

Sponsor

Aravive, Inc.